International Stem Cell Corporation to Move Forward with Traumatic Brain Injury Phase II Clinical Trial – GlobeNewswire (press release)
BioPharma-Reporter.com |
International Stem Cell Corporation to Move Forward with Traumatic Brain Injury Phase II Clinical Trial
GlobeNewswire (press release) 20, 2017 (GLOBE NEWSWIRE) — International Stem Cell Corporation (OTCQB:ISCO) (www.internationalstemcell.com) ("ISCO" or "the Company"), a California-based clinical stage biotechnology company developing novel stem cell-based therapies and … US FDA stem cell enforcement challenged by state legislation Defining the Future of the Stem Cell Market and Exclusive Interviews with Stem Cell Industry Executives in 2017 Report Embryonic Stem Cell Research Still Hasn't Cured a Single Patient |
